Fresenius Medical Care AG

NYSE:FMS Stock Report

Market Cap: US$13.7b

Fresenius Medical Care Past Earnings Performance

Past criteria checks 4/6

Fresenius Medical Care's earnings have been declining at an average annual rate of -20.9%, while the Healthcare industry saw earnings growing at 6.3% annually. Revenues have been growing at an average rate of 2.7% per year. Fresenius Medical Care's return on equity is 5.9%, and it has net margins of 3.4%.

Key information

-20.9%

Earnings growth rate

-20.4%

EPS growth rate

Healthcare Industry Growth8.5%
Revenue growth rate2.7%
Return on equity5.9%
Net Margin3.4%
Next Earnings Update25 Feb 2025

Recent past performance updates

Recent updates

Fresenius Medical Care: Let's Look At The Upside

Oct 04

Fresenius Medical Care: Significant Upside Remains

Jun 25

Broyhill - Fresenius Medical Care: Correctly Focused On Increasing Margins And Returns

Feb 23

Fresenius Medical Care: Don't Let The Ozempic Kidney Failure Scare You Off

Oct 12

Fresenius Medical Care: Other Stocks Still Better, But Upside Exists

Jun 01

Fresenius Medical Care Q4 2022 Earnings Preview

Feb 21

Fresenius: The Company Is Climbing, And I'm At 'Buy'

Jan 06

Fresenius: A Contrarian Opportunity Not Seen For 20 Years (Technical Analysis)

Oct 27

Fresenius Medical gains after report of activist Elliott stake in Fresenius SE

Oct 19

Fresenius cut to Hold at Jefferies citing staffing issues and inflation

Oct 10

Fresenius gets award to provide dialysis services to U.S. military veterans

Aug 30

Fresenius appoints head of pharma unit as new CEO

Aug 19

Fresenius Medical Care: Best Time In 21 Years To Buy This High-Yield Dividend Aristocrat

Jul 30

Fresenius Medical Care accused of Medicare fraud in dialysis

Jul 13

Fresenius: The Upside Is Getting Bigger

May 02

You Really Want To Know About Fresenius Medical Care

Aug 28

Fresenius Medical drops 12% on disappointing 2021 outlook

Feb 02

Fresenius Medical Care EPS beats by €0.06, misses on revenue

Oct 29

Revenue & Expenses Breakdown

How Fresenius Medical Care makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NYSE:FMS Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2419,2396593,148199
30 Jun 2419,4155303,186212
31 Mar 2419,4744843,190224
31 Dec 2319,4544993,196232
30 Sep 2319,4634503,156228
30 Jun 2319,6225963,180236
31 Mar 2319,5546023,163235
31 Dec 2219,3986733,170229
30 Sep 2219,0487633,104234
30 Jun 2218,3938063,018225
31 Mar 2217,9578783,091222
31 Dec 2117,6199692,773221
30 Sep 2117,3729183,011205
30 Jun 2117,3449982,986198
31 Mar 2117,5811,1312,868197
31 Dec 2017,8591,1642,966194
30 Sep 2018,0391,3302,991190
30 Jun 2018,0441,3093,016187
31 Mar 2017,8321,2123,099185
31 Dec 1917,4771,2002,944168
30 Sep 1917,1961,2822,967138
30 Jun 1916,8351,2342,978122
31 Mar 1916,7041,9742,898111
31 Dec 1816,5471,9822,857114
30 Sep 1816,6761,9513,126131
30 Jun 1816,9541,9753,185133
31 Mar 1817,2111,2503,374130
31 Dec 1717,7841,2803,640111
30 Sep 1717,7711,2493,417134
30 Jun 1717,6471,2443,407145
31 Mar 1717,2011,2393,262144
31 Dec 1616,5701,1443,133147
30 Sep 1616,1011,0633,047143
30 Jun 1615,8419983,027136
31 Mar 1615,4029332,961130
31 Dec 1515,4559552,895128
30 Sep 1515,3459392,919118
30 Jun 1515,2469482,839114
31 Mar 1515,4289772,816115
31 Dec 1413,3298642,434101
30 Sep 1412,4138392,24297
30 Jun 1411,1127751,99991
31 Mar 1410,8827911,96291
31 Dec 1310,8168061,93791

Quality Earnings: FMS has high quality earnings.

Growing Profit Margin: FMS's current net profit margins (3.4%) are higher than last year (2.3%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: FMS's earnings have declined by 20.9% per year over the past 5 years.

Accelerating Growth: FMS's earnings growth over the past year (46.5%) exceeds its 5-year average (-20.9% per year).

Earnings vs Industry: FMS earnings growth over the past year (46.5%) exceeded the Healthcare industry 10.4%.

Return on Equity

High ROE: FMS's Return on Equity (5.9%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 15:42
End of Day Share Price 2024/12/18 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Fresenius Medical Care AG is covered by 59 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Martin SchneeAlphaValue
Brian WilliamsAvondale Partners
Olav ZilianBaader Helvea Equity Research